Overview
- Editors:
-
-
V. S. Byers
-
Xoma Corporation, Berkeley, USA
-
R. W. Baldwin
-
Cancer Research Campaign Laboratories, University of Nottingham, Nottingham, UK
Access this book
Other ways to access
Table of contents (11 chapters)
-
-
-
-
- R. W. Baldwin, V. S. Byers
Pages 44-54
-
-
-
-
- F. Vánky, E. Klein, J. Willems, K. Böök, T. Ivert, A. Péterffy
Pages 105-128
-
- Ph Rümke, J. E. de Vries
Pages 129-150
-
-
- A. E. Frankel, C. M. Boyer, R. C. Bast
Pages 167-224
-
- A. Chachoua, R. Oratz, M. Green, F. M. Muggia
Pages 225-261
-
Back Matter
Pages 262-270
About this book
Over the past 5 years, clinical immunology, as a whole, has advanced more rapidly than over the past 20 years. Many of these advances have been que to monoclonal antibody technology with its ability to identify antigens on tumour cells with a precision never before available. Monoclonal antibodies have the ability to identify subsets of human T-Iymphocytes and aid in diagnosis of both immunodeficiency disorders such as AIDS, or autoimmune diseases, and they can be adapted as drug targeting agents. Additionally, however, major advances have been made in identifying immunomodulating agents, and the last year has seen two such agents, IL-2 and OKT3, made available commercially for such intervention. Furthermore, another immuno modulating technique, bone marrow transplantation, ha~ now been established as a curative modality in leukaemia treatment. A central issue in tumour immunology is whether human tumours express antigens which can be termed tumour-specific. This has important implications for both tumour immunity as well as drug targeting. This issue is considered in detail by R. A. Robins in the introductory chapter in which the expression of antigens in human tumours is compared with that in experimentally induced animal tumours. This controversial issue is also considered in later chapters by Bast in breast carcinoma, Riimke and de Vries in melanoma, V{mky in lung cancer, Armitage in colorectal cancer, and Paulie and Perlmann in bladder carcinoma.
Reviews
`This book provides an overview of many of the most recent developments in this field, with the benefit of plentiful recent references. It should be of interest both to oncologists and clinical researchers.'
Oncology Information Service.
Editors and Affiliations
-
Xoma Corporation, Berkeley, USA
V. S. Byers
-
Cancer Research Campaign Laboratories, University of Nottingham, Nottingham, UK
R. W. Baldwin
